drugset / Trial / NCT00680446
Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency
NaSingle-groupOpen-labelTreatment
Summary
The study aims to assess the safety and tolerability of subcutaneous Ig NextGen 16% in patients with Primary Immune Deficiency who require Immunoglobulin (Ig) G replacement therapy. Ig NextGen 16% is a liquid immunoglobulin (antibody) preparation.
Timeline
- Start
- 2008-04
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immunoglobulin G | Protein / enzyme biologic | — | Subcutaneous |